Tirzepatide for Obesity Treatment and Diabetes Prevention
Ania M. Jastreboff(Yale University), Irina Jouravskaya(Eli Lilly (United States)), Sean Wharton(University of Toronto), Mathijs C. Bunck(Eli Lilly (United States)), John Wilding(World Obesity Federation), Louis J. Aronne(Cornell University), Bruno Halpern(Cornell University), Shuyu Zhang(Soochow University), Adam Stefański(Eli Lilly (United States)), Nadia N. Ahmad(Eli Lilly (United States)), Carel W. le Roux(University College Dublin), Ramakrishna Battula(Eli Lilly (United States)), Leigh Perreault(University of Colorado Denver)
Cited by 368
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k
American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity
|Endocrine Practice|2016|1.8k
Inhibition of Food Intake in Obese Subjects by Peptide YY<sub>3–36</sub>
|New England Journal of Medicine|2003|1.6k
Obesity in adults: a clinical practice guideline
|Canadian Medical Association Journal|2020|1.4k